FTT PET/CT in Metastatic Prostate Cancer
About this study
Up to 30 men with metastatic prostate cancer will undergo up to 2 FTT PET/CT scans to look at PARP activity in sites of known cancer. Subjects will undergo a baseline scan prior to starting new therapy and a second, optional, post-therapy scan 1-21 days after the start of treatment. Tissue from a clinical or research biopsy will be compared to imaging measures, if available.
- Condition
- Prostate Cancer Metastatic
- Tested
- [18F]FluorThanatrace
- Sponsor
- Abramson Cancer Center at Penn Medicine
Who can join
- Age
- 18 years and older
- Sex
- Male only
- Healthy volunteers
- Not stated
Inclusion 8
- Minimum age: 18 years
- Eligible sex: Male
- Study condition: Prostate Cancer Metastatic
- Participants will be ≥ 18 years of age
- Histologically proven prostate carcinoma
- Clinical evidence of metastatic disease with at least one lesion identified on standard of care imaging (CT, MRI, Bone Scan, FDG or other PET/CT, Ultrasound)
- Considered a candidate for new therapy or change in therapy with PARP inhibitor therapy and/or androgen deprivation therapy (ADT) and/or chemotherapy with or without additional agents, either on a clinical trial or as part of clinical care.
- Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.
Exclusion 2
- Inability to tolerate imaging procedures in the opinion of an investigator or treating physician
- Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study
Where
1 site, 1 recruiting
University of Pennsylvania Hospital
Philadelphia, Pennsylvania, United States
Contact
-
Erin Schubert, BA
215-573-6569 erin.schubert@pennmedicine.upenn.edu
-
Ashley Veronsky, BA
215-898-4346 ashley.veronsky@pennmedicine.upenn.edu
Potential match only. Final eligibility is determined by the study team.